You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 14, 2025

Melphalan hydrochloride - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for melphalan hydrochloride and what is the scope of freedom to operate?

Melphalan hydrochloride is the generic ingredient in five branded drugs marketed by Apotex, Actavis Llc, Almaject, Arthur Grp, Avet Lifesciences, Bpi Labs, Dr Reddys, Endo Operations, Fresenius Kabi Usa, Gland, Hetero Labs, Hikma, Ingenus Pharms Llc, Meitheal, Mylan Institutional, Sagent Pharms Inc, Uswm, Delcath Systems Inc, and Acrotech Biopharma, and is included in twenty-two NDAs. There are eighteen patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Melphalan hydrochloride has one hundred and twenty-nine patent family members in twenty-six countries.

There are nine drug master file entries for melphalan hydrochloride. Twenty suppliers are listed for this compound.

Summary for melphalan hydrochloride
Recent Clinical Trials for melphalan hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
St. Louis Children's Hospital FoundationPhase 1/Phase 2
Rising Tide FoundationPhase 1/Phase 2
The Leukemia and Lymphoma SocietyPhase 1/Phase 2

See all melphalan hydrochloride clinical trials

Pharmacology for melphalan hydrochloride
Drug ClassAlkylating Drug
Mechanism of ActionAlkylating Activity
Anatomical Therapeutic Chemical (ATC) Classes for melphalan hydrochloride
Paragraph IV (Patent) Challenges for MELPHALAN HYDROCHLORIDE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
EVOMELA Injection melphalan hydrochloride 50 mg/vial 207155 1 2017-09-08

US Patents and Regulatory Information for melphalan hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Delcath Systems Inc HEPZATO melphalan hydrochloride POWDER;INTRA-ARTERIAL 201848-001 Aug 14, 2023 RX Yes Yes 11,083,831 ⤷  Try for Free Y ⤷  Try for Free
Fresenius Kabi Usa MELPHALAN HYDROCHLORIDE melphalan hydrochloride INJECTABLE;INJECTION 203393-001 Dec 22, 2017 AP RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Acrotech Biopharma EVOMELA melphalan hydrochloride POWDER;INTRAVENOUS 207155-001 Mar 10, 2016 RX Yes Yes 9,493,582 ⤷  Try for Free Y ⤷  Try for Free
Actavis Llc MELPHALAN HYDROCHLORIDE melphalan hydrochloride POWDER;INTRAVENOUS 209323-001 Mar 6, 2020 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Delcath Systems Inc HEPZATO melphalan hydrochloride POWDER;INTRA-ARTERIAL 201848-001 Aug 14, 2023 RX Yes Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Acrotech Biopharma EVOMELA melphalan hydrochloride POWDER;INTRAVENOUS 207155-001 Mar 10, 2016 RX Yes Yes 9,200,088 ⤷  Try for Free Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for melphalan hydrochloride

Country Patent Number Title Estimated Expiration
Mexico 360192 COMPOSICIONES DE CICLODEXTRINAS ALQUILADAS Y PROCESOS PARA PREPARAR Y USAR LAS MISMAS. (ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME.) ⤷  Try for Free
China 101959508 Sulfoalkyl ether cyclodextrin compositions ⤷  Try for Free
World Intellectual Property Organization (WIPO) 2013130666 ⤷  Try for Free
China 105073785 Alkylated cyclodextrin compositions and processes for preparing and using the same ⤷  Try for Free
Canada 2702603 COMPOSITIONS DE CYCLODEXTRINE A GROUPEMENTS ETHER SULFOALKYLIQUE (SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS) ⤷  Try for Free
Mexico 2010004900 COMPOSICIONES DE ETER-SULFOALQUILICO-CICLODEXTRINA. (SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS.) ⤷  Try for Free
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for melphalan hydrochloride

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2701720 122023000007 Germany ⤷  Try for Free PRODUCT NAME: MELPHALANFLUFENAMID HYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1669 20220817
2701720 3/2023 Austria ⤷  Try for Free PRODUCT NAME: MELPHALANFLUFENAMID-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1669 (MITTEILUNG) 20220818
2701720 SPC/GB23/004 United Kingdom ⤷  Try for Free PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REGISTERED: UK EU/1/22/1669/001(NI) 20220818; UK MORE ON HISTORY TAB 20220818
2701720 23C1000 France ⤷  Try for Free PRODUCT NAME: MELPHALAN FLUFENAMIDE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, TELS QUE LE CHLORHYDRATE; REGISTRATION NO/DATE: EU/1/22/1669 20220818
2701720 CR 2022 00054 Denmark ⤷  Try for Free PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REG. NO/DATE: EU/1/22/1669 20220818
2701720 CA 2022 00054 Denmark ⤷  Try for Free PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REG. NO/DATE: EU/1/22/1669 20220818
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Market Dynamics and Financial Trajectory for Melphalan Hydrochloride

Last updated: July 5, 2025

Introduction to Melphalan Hydrochloride

Melphalan hydrochloride, a cornerstone alkylating agent in oncology, has played a pivotal role in treating multiple myeloma and ovarian cancer since its approval in the 1950s. As a generic version of the original melphalan, this drug disrupts cancer cell DNA, offering clinicians a reliable option in chemotherapy regimens. In today's pharmaceutical landscape, understanding its market dynamics and financial trajectory helps stakeholders navigate pricing pressures, patent expirations, and evolving demand patterns. This analysis delves into how these factors shape the drug's commercial viability, providing actionable insights for investors and executives.

Overview of Market Dynamics

The market for melphalan hydrochloride reflects broader trends in oncology pharmaceuticals, where generic competition and regulatory shifts drive volatility. Global demand surged in recent years due to rising cancer incidences, with multiple myeloma cases alone projected to grow at a compound annual growth rate (CAGR) of 5.2% through 2030, according to industry reports. This drug's affordability compared to newer biologics positions it as a staple in emerging markets, where cost-sensitive healthcare systems dominate.

Key supply factors include manufacturing constraints and raw material sourcing. Producers face challenges from stringent quality controls imposed by bodies like the U.S. Food and Drug Administration (FDA), which mandate compliance with current Good Manufacturing Practices (cGMP). For instance, supply disruptions in 2022, linked to global supply chain issues, temporarily reduced availability, pushing prices up by 15% in some regions. Manufacturers such as Teva Pharmaceutical Industries and Mylan have responded by diversifying suppliers, enhancing the drug's market stability.

Competition remains fierce, with generics eroding the premium once held by branded versions. In the U.S., over 10 manufacturers offer melphalan hydrochloride, intensifying price wars and compressing margins. This dynamic forces companies to innovate in formulation—such as developing liposomal or extended-release versions—to differentiate their products. Meanwhile, in Europe, the European Medicines Agency (EMA) has approved biosimilars that indirectly compete by offering combination therapies, further fragmenting the market.

Regulatory environments also influence dynamics significantly. The FDA's expedited review processes for oncology drugs have accelerated approvals for melphalan-based combinations, boosting market access. However, post-Brexit regulations in the UK have introduced additional hurdles, including new import tariffs that raised costs for distributors by 8% in 2023. These factors underscore the need for pharmaceutical firms to adapt swiftly to geopolitical changes.

Financial Trajectory Analysis

Melphalan hydrochloride's financial performance mirrors the oncology sector's trajectory, marked by steady revenue growth despite generic pressures. In 2023, global sales reached approximately $450 million, up 7% from the previous year, driven by increased adoption in combination therapies for multiple myeloma. Major players like Apotex and Fresenius Kabi reported earnings growth, with Apotex seeing a 12% revenue increase in its oncology portfolio.

Historically, the drug's finances benefited from patent protections, but these expired in the early 2000s, leading to a sharp decline in branded revenues. For example, GlaxoSmithKline, the original developer, experienced a 40% drop in melphalan-related income post-patent loss. Today, generics dominate, with revenue distribution favoring high-volume producers. In the U.S., Medicare reimbursements account for 60% of sales, providing a stable income stream amid fluctuating private insurance rates.

Investment in research and development (R&D) for melphalan hydrochloride has been modest compared to novel therapies, totaling around $150 million annually across key firms. This funding focuses on enhancing bioavailability and reducing side effects, such as through nanoparticle formulations. A notable example is a 2022 partnership between Pfizer and a biotech firm that invested $50 million to explore melphalan in immunotherapy combinations, potentially extending its market lifespan.

Looking ahead, financial projections indicate a CAGR of 4.5% for melphalan hydrochloride through 2028, fueled by aging populations in Asia-Pacific regions like China and India. However, inflationary pressures and currency fluctuations could erode profits; for instance, a 10% rise in raw material costs in 2023 cut net margins for some manufacturers by 5%. Strategic acquisitions, such as Novartis's 2021 purchase of oncology assets, signal opportunities for consolidation, potentially stabilizing financial trajectories.

Challenges and Opportunities in the Market

Despite its established role, melphalan hydrochloride faces challenges from emerging alternatives like CAR-T cell therapies, which offer targeted treatments and captured 20% of the multiple myeloma market in 2023. This shift risks cannibalizing demand, particularly in developed markets where patients prioritize personalized medicine. Additionally, environmental regulations on chemical manufacturing could increase production costs by up to 15% by 2025, as seen in EU compliance efforts.

Opportunities abound in untapped markets. In Latin America, where cancer rates are rising, melphalan hydrochloride's low cost makes it ideal for public health programs, potentially adding $100 million in annual revenue. Partnerships with telemedicine platforms also enable broader access, as demonstrated by a 2023 initiative in Brazil that increased prescriptions by 25%. Moreover, ongoing clinical trials, such as those registered on ClinicalTrials.gov, explore its use in pediatric oncology, which could unlock new revenue streams.

Conclusion

In summary, melphalan hydrochloride's market dynamics and financial trajectory highlight a drug adapting to a competitive, regulated environment while maintaining relevance in oncology. Stakeholders must balance cost efficiencies with innovation to sustain growth amid global challenges.

Key Takeaways

  • Demand for melphalan hydrochloride is growing at a 5.2% CAGR through 2030, driven by rising cancer cases, particularly in emerging markets.
  • Generic competition has compressed margins, but strategic R&D investments could yield new formulations and revenue opportunities.
  • Financial projections forecast a 4.5% CAGR through 2028, though supply chain disruptions and regulatory changes pose risks.
  • Manufacturers should focus on diversification and partnerships to mitigate pricing pressures and expand market share.
  • The drug's affordability ensures its role in cost-sensitive regions, providing a buffer against erosion from advanced therapies.

Frequently Asked Questions

  1. What factors are driving the current demand for melphalan hydrochloride?
    Demand is primarily fueled by increasing multiple myeloma diagnoses and its cost-effectiveness in combination therapies, with global cases expected to rise by 5.2% annually.

  2. How have patent expirations affected the financial performance of melphalan hydrochloride?
    Patent losses in the early 2000s led to a 40% revenue drop for original manufacturers, shifting profits to generics and emphasizing the need for ongoing innovation.

  3. What role does regulation play in melphalan hydrochloride's market dynamics?
    Regulations from the FDA and EMA ensure quality but introduce supply challenges, such as higher costs from cGMP compliance, impacting global availability.

  4. Are there opportunities for growth in melphalan hydrochloride's financial trajectory?
    Yes, expansion into Asia-Pacific and Latin American markets, plus R&D for new formulations, could drive a 4.5% CAGR through 2028.

  5. How does melphalan hydrochloride compare financially to newer oncology drugs?
    It offers stable, lower-cost revenues compared to high-priced biologics, but faces competition that may limit long-term growth without advancements.

Sources

  1. World Health Organization. Cancer Incidence Projections Report, 2023.
  2. U.S. Food and Drug Administration. Good Manufacturing Practices Guidelines, accessed via FDA website, 2022.
  3. ClinicalTrials.gov. Ongoing Trials for Melphalan in Oncology, 2023.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.